| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Medicare | 361.7 | 471.2 | 516.8 | 447.0 | 210.6 | 142.4 | 122.2 | 63.2 |
| Individual, Family and Small Business | 43.7 | 67.0 | 66.0 | 59.2 | 40.8 | 48.3 | 71.2 | |
| Individual, Family and Small Business Segment | | | | | | | | 126.4 |
| Total revenues [+] | 405.4 | 538.2 | 582.8 | 506.2 | 251.4 | 190.7 | 193.3 | 189.5 |
| Insurance commissions & fees | | | | | | | 177.2 | 171.3 |
| Other | | | | | | | 16.1 | 18.3 |
| Revenue growth [+] | -24.7% | -7.6% | 15.1% | 101.4% | 31.8% | -1.4% | 2.0% | 5.5% |
| Medicare | -23.2% | -8.8% | 15.6% | 112.3% | 47.8% | 16.6% | 93.4% | 42.0% |
| Individual, Family and Small Business | -34.8% | 1.5% | 11.4% | 45.1% | -15.4% | -32.2% | | |
| Cost of goods sold | 1.6 | 2.0 | 4.1 | 2.7 | 1.2 | 0.6 | 0.9 | 4.2 |
| Gross profit | 403.7 | 536.2 | 578.7 | 503.5 | 250.2 | 190.1 | 192.5 | 185.4 |
| Gross margin | 99.6% | 99.6% | 99.3% | 99.5% | 99.5% | 99.7% | 99.6% | 97.8% |
| Selling, general and administrative [+] | 266.9 | 347.0 | 285.8 | 214.4 | 128.8 | 105.8 | 107.4 | 105.8 |
| Sales and marketing | 195.1 | 271.3 | 209.3 | 150.2 | 82.9 | 65.9 | 72.2 | 75.6 |
| General and administrative | 71.8 | 75.7 | 76.5 | 64.2 | 45.8 | 40.0 | 35.2 | 30.2 |
| Research and development | 78.8 | 83.8 | 65.2 | 47.1 | 32.0 | 32.9 | 32.7 | 36.4 |
| Other operating expenses | 141.1 | 133.0 | 172.9 | 134.3 | 70.5 | 59.2 | 49.8 | 44.3 |
| EBITDA [+] | -79.3 | -22.1 | 58.5 | 110.7 | 21.4 | -5.0 | 7.1 | 4.2 |
| EBITDA growth | 258.4% | -137.8% | -47.1% | 418.0% | -531.2% | -169.7% | 69.5% | -502.6% |
| EBITDA margin | -19.6% | -4.1% | 10.0% | 21.9% | 8.5% | -2.6% | 3.7% | 2.2% |
| Depreciation | 3.8 | 5.4 | 3.7 | 3.0 | 2.5 | 2.8 | 3.5 | 4.1 |
| EBITA | -83.1 | -27.5 | 54.8 | 107.7 | 18.9 | -7.8 | 3.6 | 0.0 |
| EBITA margin | -20.5% | -5.1% | 9.4% | 21.3% | 7.5% | -4.1% | 1.8% | 0.0% |
| Amortization of intangibles | | 0.5 | 1.5 | 2.2 | 2.1 | 1.0 | 1.0 | 1.2 |
| EBIT [+] | -83.1 | -28.1 | 53.3 | 105.5 | 16.8 | -8.8 | 2.5 | -1.1 |
| EBIT growth | 195.9% | -152.7% | -49.5% | 528.2% | -290.1% | -449.6% | -327.6% | -83.6% |
| EBIT margin | -20.5% | -5.2% | 9.1% | 20.8% | 6.7% | -4.6% | 1.3% | -0.6% |
| Non-recurring items [+] | 19.6 | 97.6 | | 24.1 | 14.2 | 0.6 | -0.3 | 4.5 |
| Asset impairment | | 46.3 | | | | | | |
| Loss on contingent liability | | | | 24.1 | 12.3 | | | |
| Other income (expense), net [+] | -3.7 | 0.8 | 0.7 | 2.1 | 0.8 | 1.2 | 1.1 | 0.0 |
| Other | -3.7 | 0.8 | 0.7 | 2.1 | 0.8 | 1.2 | 1.1 | 0.0 |
| Pre-tax income | -106.4 | -124.9 | 54.0 | 83.5 | 3.3 | -8.3 | 4.0 | -5.6 |
| Income taxes | -17.7 | -20.5 | 8.5 | 16.6 | 3.1 | -33.7 | 3.7 | -0.8 |
| Tax rate | 16.6% | 16.4% | 15.8% | 19.9% | 92.7% | 407.4% | 92.3% | 15.0% |
| Net income | -119.4 | -122.9 | 45.5 | 66.9 | 0.2 | 25.4 | 0.3 | -4.8 |
| Net margin | -29.5% | -22.8% | 7.8% | 13.2% | 0.1% | 13.3% | 0.2% | -2.5% |
| |
| Basic EPS [+] | ($4.36) | ($4.59) | $1.75 | $2.90 | $0.01 | $1.37 | $0.02 | ($0.26) |
| Growth | -4.9% | -362.9% | -39.8% | 23106.3% | -99.1% | 8155.4% | -106.3% | -70.0% |
| Diluted EPS [+] | ($4.36) | ($4.59) | $1.68 | $2.73 | $0.01 | $1.33 | $0.02 | ($0.26) |
| Growth | -4.9% | -372.9% | -38.3% | 22982.9% | -99.1% | 7941.9% | -106.3% | -70.0% |
| |
| Shares outstanding (basic) [+] | 27.4 | 26.8 | 26.0 | 23.1 | 19.3 | 18.5 | 18.3 | 18.0 |
| Growth | 2.2% | 2.9% | 12.8% | 19.6% | 4.2% | 1.3% | 1.5% | -2.0% |
| Shares outstanding (diluted) [+] | 27.4 | 26.8 | 27.0 | 24.5 | 20.4 | 19.0 | 18.3 | 18.0 |
| Growth | 2.2% | -0.9% | 10.1% | 20.2% | 7.2% | 4.0% | 1.7% | -2.0% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |